abstract: A male to female ration of @entity301 :1 has been a consistent finding. This differential persists event when the classic risk factors for @entity101 , smoking, @entity28 , @entity6 , and @entity407 --are controlled for gender. The most likely ultimate cause of this phenomenon is male-female differences in sex hormone patterns. Clinical studies in this area have either compared the sex hormone profiles of @entity1 and @entity1 with and without @entity301 or computed the relative prevalence of disease in populations that differ in their sex hormone patterns. In general, research findings have disputed the hypothesis that @entity1 with @entity301 have low levels of a protective factor such as @entity172 or @entity1420 and high levels of @entity251 . @entity301 @entity1 actually have elevated @entity172 levels and low @entity251 levels; endogenous @entity1420 levels are normal before @entity1188 but show a stress-mediated increase in the immediate postinfarction period. Findings of a low prevalence of @entity301 in premenopausal @entity1 , a loss of protection after menopause, and a low prevalence of @entity301 in @entity1 with @entity82 -related hyperestrogenemia suggest that natural @entity172 are antiatherogenic. The protective effect of pregnancy against @entity583 , despite concomitant potentially thrombogenic levels of @entity172 at the time, seems to indicate that @entity1420 , whose levels are also extremely high during pregnancy, plays a major anti- @entity1188 protective effect distinct from that of @entity172 . Studies of @entity1 oral contraceptive (OC) users and @entity1 taking @entity172 for brief periods have found that these exogenous hormones produce coronary @entity715 but not @entity731 . Finally, the finding of increased @entity301 risk in long-term OC users indicates that synthetic @entity172 favor @entity453 by suppressing natural @entity172 and @entity1420 production.

title: Sex hormones and XXXX : a review of the clinical studies.

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'persons', 'women', 'patients']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogens', 'estrogen']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['coronary disease--hypertension']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary disease of 2', 'Coronary disease', 'coronary disease']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarction']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary atherosclerosis']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity301 :: (MESH:D003327,Disease) :: ['coronary disease']


abstract: STUDY OBJECTIVE: To determine the effect of an outpatient program designed to reduce readmissions for @entity565 exacerbations among adults with @entity565 . DESIGN: Randomized @entity1 selection with crossover. SETTING: Bellevue Hospital, New York City, New York. @entity1 : We identified 104 adult asthmatics who had previously required multiple hospitalizations for @entity565 attacks. Forty-seven @entity1 were randomly assigned to an intensive outpatient treatment clinic and 57 @entity1 continued to receive their previous outpatient care. Nineteen @entity1 from this latter group were then crossed to the intensive outpatient therapy clinic. INTERVENTIONS: Attenders of the intensive outpatient treatment program were treated with a vigorous medical regimen and educational program. Emphasis was placed on teaching @entity1 aggressive self-management strategies in case of marked @entity565 exacerbation. MEASUREMENTS AND MAIN RESULTS: The main measurement used to determine efficacy of the study program was readmission rate and hospital days used. Prospective comparison of treated compared with untreated @entity1 indicated that program enrollment resulted in a threefold reduction in readmission rate and a twofold reduction in hospital day use rate (P less than 0.004 and P less than 0.02, respectively). Using retrospective data with @entity1 serving as their own controls, we found a threefold reduction in readmission rate and in hospital day use (P less than 0.003) during a 32-month follow-up period. A similar magnitude of reduction in hospital utilization was found when @entity1 were crossed over to the intensive treatment group (P less than 0.004). CONCLUSIONS: By using a vigorous medical regimen and intensive educational program, we were able to decrease hospital use among a group of adult asthmatics who had previously required repeated readmissions for acute @entity565 exacerbations.

title: Results of a program to reduce admissions for adult XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients', 'patient']

answer: @entity565 :: (MESH:D001249,Disease) :: ['asthma']


abstract: BACKGROUND: The pathogenesis of arterial @entity715 involves multiple genetic and environmental factors related to @entity731 and @entity715 . But, there have been very few studies in India which have investigated some of the @entity49 markers. AIM: To look for combined @entity49 in MI @entity1 . SETTINGS AND DESIGN: One hundred twenty @entity1 of @entity583 (age below 40 yrs.) were recruited 8-10 weeks after stabilization. Hundred age and sex-matched healthy controls were also recruited in the present study. METHODS AND MATERIAL: Following @entity49 markers were screened in these @entity1 --plasma @entity2002 , protein C, protein S, antithrombin III, @entity5337 , PT @entity14553 polymorphism, @entity9769 @entity9770 , @entity1255 , @entity2002 b448 Arg/Lys polymorphism and CBS @entity26330 mutation. STATISTICAL ANALYSIS: Statistical analysis was done using Statistical Package for Social Sciences (SPSS) version 10.0, SPSS Inc., Chicago, USA. RESULTS AND CONCLUSION: Elevated @entity2002 levels, @entity1255 (p< 0.001 and @entity1255 with odds ratio 6.26) and @entity5337 (p=0.038) were independently associated with MI in our @entity1 . A total of 37 @entity1 (42.5%) had the presence of more than one @entity49 markers in combination. Out of these, 10 had the presence of three markers in combination and 1 had five @entity49 markers in combination. Only 2 controls had prothrombotic markers in combination. Combined prothrombotic risk factors were significant in cases in comparison to controls (p< 0.001). Further larger studies on a nationwide basis recruiting a large number of young MI @entity1 should be done to substantiate these findings.

title: Combination of @entity49 markers in XXXX of the young.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1255 :: ('MESH:D006710', 'Chemical') :: ['homocysteine']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['thrombophilia']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic disease']

answer: @entity583 :: (MESH:D009203,Disease) :: ['acute myocardial infarction']


abstract: Specific causes of @entity204 were analyzed for 10,908 @entity1 in the @entity101 Detection and Follow-up Program, to explore possible explanations for the observed excess 8.3-year mortality from all causes in @entity101 with low body mass. Although the @entity65 rate among @entity1 in the lowest decile of body mass (body mass index 21.96 or less) was 50% higher than that of @entity1 in the median class (body mass index 26.4-28.8), @entity204 rate for noncardiovascular @entity204 was more than 2 1/2 times higher in @entity1 with lean versus median body mass. The pattern was similar among @entity1 . Among noncardiovascular causes, striking differences in mortality rates between lean @entity101 and those of average body mass were observed for @entity204 (relative risk of 12+ in @entity1 and 11+ in @entity1 ), for nonmalignant @entity1576 in @entity1 (relative risk of 7+), for @entity204 (both sexes), and for @entity5 in @entity1 . Prevalence of smoking was almost twice as high in the lowest compared with the median body mass group; among the lean, excess @entity204 , particularly noncardiovascular @entity204 , were concentrated among smokers. Thus, male smokers in the lowest decile of body mass constituted only 3% of the study population, but contributed 8% of all @entity204 , 11% of all noncardiovascular @entity204 , and 22% of all cirrhotic @entity204 . A larger proportion of @entity204 occurred early in follow-up in the lean versus other @entity101 , suggesting @entity66 among the lean at baseline. There was no evidence that more severe or treatment-resistant @entity101 was present in or could explain excess mortality among the @entity101 with low body mass. The inference from the findings is not that overweight is protective for @entity101 nor that excess risk is due to leanness per se. Rather, a reasonable hypothesis, particularly from findings on specific causes of @entity204 , is that excess mortality in lean @entity101 is due to deleterious lifestyles, particularly smoking and excess @entity167 intake, contributing to both leanness and risk of @entity204 .

title: Why do lean @entity101 have higher mortality rates than other XXXX ? Findings of the @entity101 Detection and Follow-up Program.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'men', 'women']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensives', 'hypertension', 'Hypertension']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['occult disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant neoplasms']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['cirrhotic death', 'deaths', 'violent death', 'death']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertensives']


abstract: BACKGROUND: @entity548 /resuscitation is associated with aberrant neutrophil activation and organ failure. This experimental porcine study was done to evaluate the effects of Fas-directed extracorporeal immune therapy with a leukocyte inhibition module (LIM) on hemodynamics, neutrophil tissue infiltration, and tissue damage after @entity548 /resuscitation. METHODS: In a prospective controlled double-armed animal trial 24 Munich Mini @entity1707 (30.3 +/- 3.3 kg) were rapidly haemorrhaged to reach a @entity551 ( @entity551 ) of 35 +/- 5 mmHg, maintained @entity551 for 45 minutes, and then were resuscitated with Ringer' solution to baseline @entity551 . With beginning of resuscitation 12 @entity1707 underwent extracorporeal immune therapy for 3 hours (LIM group) and 12 @entity1707 were resuscitated according to standard medical care (SMC). Haemodynamics, haematologic, metabolic, and organ specific damage parameters were monitored. Neutrophil infiltration was analyzed histologically after 48 and 72 hours. Lipid peroxidation and apoptosis were specifically determined in lung, bowel, and liver. RESULTS: In the LIM group, neutrophil counts were reduced versus SMC during extracorporeal immune therapy. After 72 hours, the @entity998 (CO) were significantly better in the LIM group. Histological analyses showed reduction of shock-related neutrophil tissue infiltration in the LIM group, especially in the lungs. Lower amounts of apoptotic cells and lipid peroxidation were found in organs after LIM treatment. CONCLUSIONS: Transient Fas-directed extracorporeal immune therapy may protect from posthemorrhagic neutrophil tissue infiltration and tissue damage.

title: Extracorporeal immune therapy with immobilized agonistic anti-Fas antibodies leads to transient reduction of circulating neutrophil numbers and limits tissue damage after XXXX /resuscitation in a porcine model.

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive', 'MAP', 'mean arterial pressure']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['Hemorrhagic shock', 'hemorrhagic shock']

entities_list: @entity998 :: ('MESH:D002303', 'Disease') :: ['haemodynamic parameters MAP and cardiac output']

answer: @entity548 :: (MESH:D006470,Disease) :: ['hemorrhagic shock']


abstract: A fully documented series of thirty nine cases of @entity84 is described. This is a remarkable series because of the rarity of this @entity5 . There is a slight predilection for the male sex. The age most affected is ten to twenty years. The @entity5 progresses @entity2720 and @entity158 are slight. The commonest site is the proximal epiphysis of the humerus, followed by the epiphyses of the knee. The classical appearances are of a clearly defined area of @entity3061 , central or eccentric, with foci of @entity730 , in the epiphyseal or apophyseal regions, and often transgressing the epiphyseal cartilage. We have never observed involvement of the opposite bone in the affected joint. In four of our thirty nine cases the @entity5 invaded the point and/or soft tissues. The differential diagnosis, especially in localisations at the knee, is with @entity5 . The @entity5 is slow growing and the prognosis is always good. We have never seen malignant transformations or so-called "benign" pulmonary metastases. The few recurrences in this series (five out of thirty nine) were all cured by a second operation. Curettage and grafting is the operation of choice.

title: XXXX (a study of 39 cases).

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['giant cell tumour', 'neoplasm', 'tumour']

entities_list: @entity730 :: ('MESH:D002114', 'Disease') :: ['calcification']

entities_list: @entity3061 :: ('MESH:D010014', 'Disease') :: ['osteolysis']

entities_list: @entity84 :: ('MESH:D002804', 'Disease') :: ['epiphyseal chondroblastoma']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['slowly and joint involvement']

answer: @entity84 :: (MESH:D002804,Disease) :: ['Epiphyseal chondroblastoma']


abstract: We compared the clinical responses and @entity137 between @entity1749 -based salvage chemotherapy combined with @entity786 , @entity2816 , and @entity619 (Vel-CTD) and without @entity2816 (Vel-CD) in @entity1 with relapsed or refractory MM. Eighty-six @entity1 received at least two cycles of treatment with Vel-CTD ( @entity1749 1.3 mg/m2 i.v. on days 1, 4, 8, and 11; @entity786 150 mg/m2 orally on days 1   4; @entity2816 50   100 mg/day orally every day; and @entity619 20 mg/m2 i.v. on days 1, 4, 8, and 11 every 3 weeks), and 67 @entity1 were given at least two cycles of Vel-CD, which is the same regimen as Vel-CTD except without @entity2816 . The overall response rates of the Vel-CD and Vel-CTD groups were 88% and 90% (p>0.05), respectively. There was no difference in the progression free survival (p = 0.69) and overall survival rates(p = 0.49) between the two groups. Grade 3 or more adverse hematologic events occurred in the same proportion of @entity1 in both groups. In terms of @entity1503 , the Vel-CTD group showed a higher proportion of @entity4148 , @entity1897 , and @entity16 compared to the Vel-CD group (each, p<0.05). Only three @entity1 in the Vel-CTD group showed @entity715 events despite aspirin prophylaxis. The Vel-CD regimen inpatients with relapsed or refractory MM is an effective and more tolerable salvage therapy compared to Vel-CTD in terms of its comparable response rate and less severe of @entity1503 .

title: A comparison of @entity1749 , @entity786 , and XXXX (Vel-CD) chemotherapy without and with @entity2816 (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['sensory neuropathy']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['non-hematologic toxicities']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['motor neuropathy']

entities_list: @entity4148 :: ('MESH:D001342', 'Disease') :: ['autonomic neuropathy']

entities_list: @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: OBJECTIVES: This study evaluated the efficacy and tolerability of @entity972 -competitive acid blocker (P-CAB), a new class of gastric acid inhibitory agents, as first-line @entity1534 eradication treatment compared with 7-day proton pump inhibitor (PPI)-based triple therapy. METHODS: We retrospectively reviewed the medical records of 661 consecutive @entity1 who received first-line @entity1534 eradication treatment between January 2013 and October 2015. @entity1 who received 7-day P-CAB therapy (vonoprazan 20   mg+ @entity115 750   mg+ @entity4581 200   mg twice/day; n=181) were compared with those who received 7-day PPI therapy ( @entity9311 30   mg/ @entity34070 20   mg+ @entity115 750   mg+ @entity4581 200   mg twice/day; n=480) using propensity score matching analysis. The successful eradication and adverse event rates were compared between the two groups. RESULTS: The propensity score matching analysis yielded 175 matched pairs. Adjusted comparisons between the two groups showed a significantly higher eradication rate for the P-CAB than the PPI group in both intention-to-treat (89.1 vs. 70.9%; P<0.001) and per-protocol analyses (91.2 vs. 71.7%; P<0.001). There was no significant difference in the incidence of adverse events between the two therapies except @entity1910 . No @entity1 discontinued @entity1534 eradication treatment because of adverse events. CONCLUSIONS: Seven-day P-CAB-based triple therapy was more effective than 7-day PPI-based triple therapy as a first-line @entity1534 eradication treatment. Seven-day P-CAB-based triple therapy was generally well-tolerated.Am J Gastroenterol advance online publication, 17 May 2016; doi:10.1038/ajg.2016.182.

title: The Efficacy and Tolerability of a Triple Therapy Containing a @entity972 -Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose XXXX Triple Therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity34070 :: ('MESH:D064750', 'Chemical') :: ['rabeprazole']

entities_list: @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin']

entities_list: @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin']

entities_list: @entity9311 :: ('MESH:D064747', 'Chemical') :: ['lansoprazole']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

answer: @entity4581 :: (MESH:D017291,Chemical) :: ['Clarithromycin']


abstract: PURPOSE: To compare the efficacy of @entity2756 before skin incision and after cord clamping in preventing post-operative @entity166 morbidity and neonatal outcome in elective caesarean section and to determine the effect of antibiotic prophylaxis before skin incision on neonatal outcome. METHODS: Our study was a randomised controlled trial conducted among 874 @entity1 undergoing elective caesarean section from October 2010 to July 2012. These @entity1 were randomly categorised into two groups with 437 @entity1 in each group. Group 1 received single dose of @entity2756 1 g intravenously 15-45 min before skin incision. Group 2 received the antibiotic after cord clamping. Primary outcome measures were maternal post-operative @entity166 morbidities like surgical site wound @entity281 , febrile morbidity, @entity7288 , @entity293 and @entity295 . Results were analysed using Chi-square test and unpaired t test. RESULTS: Surgical site wound @entity281 occurred in 3 @entity1 in group 1 (0.7%) and 6 @entity1 in group 2 (1.4%). @entity221 occurred in 9 @entity1 in group 1 (2.1%) and 5 in group 2 (1.1%) with the p value of 0.419, not statistically significant. @entity293 occurred in 9 @entity1 in group 1 (2.1%) and 7 @entity1 in group 2 (1.6%) with the p value of 0.801. None of the @entity1 in either group developed @entity7288 . About 20 neonates [10 neonates (2.3%) in group 1 and 10 neonates (2.3%) in group 2] required NICU admission after caesarean delivery. The reasons for admission were respiratory distress, @entity3465 and @entity154 . About 0.9% of neonates in group 1 and 1.8% in group 2 developed @entity295 with positive blood culture (p = 0.388). CONCLUSION: Timing of administration of prophylactic antibiotics for elective caesarean section either before skin incision or after cord clamping did not have significant difference in the occurrence of post-operative @entity166 morbidity. No adverse neonatal outcome was observed in @entity1 who received the antibiotic before skin incision.

title: Comparison of administration of single dose XXXX for elective caesarean section before skin incision and after cord clamping in preventing post-operative @entity166 morbidity.

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital anomaly']

entities_list: @entity2756 :: ('MESH:D002443', 'Chemical') :: ['ceftriaxone']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['neonatal sepsis']

entities_list: @entity7288 :: ('MESH:D004716', 'Disease') :: ['endometritis']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['prematurity']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infections', 'Urinary tract infection']

answer: @entity2756 :: (MESH:D002443,Chemical) :: ['ceftriaxone']


abstract: When a candidate for aortocoronary bypass has an associated lesion of the aorta orone of its major branches, a single operation may be indicated for correction of both problems. Three typical cases illustrate the concept of the combined approach to surgical management of coronary arterial lesions and associated @entity2998 , @entity1028 , and superficial-femoral @entity455 . An aortocoronary bypass candidate with @entity543 may be in imminent danger of both @entity583 and @entity64 . The selection of the proper sequence of operations under these circumstances is extremely important because any form of @entity551 might produce a @entity64 . Cardiopulmonary bypass usually results in at least a transient @entity551 which would further compromise the blood flow across the tight stenosis of the carotid artery. Therefore, we recommended repair of the carotid lesion before aortocoronary bypass is attempted in order to avoid the possibility of @entity64 . The combined presence of @entity453 and @entity1028 is indication for operation, but resection of the @entity439 involves cross-clamping of the aorta, and subsequent changes in arterial pressure might impair the coronary circulation and lead to @entity583 . On the other hand, the systemic heparinization required for the establishment of cardiopulmonary bypass and arterial pressure changes could affect the integrity of @entity439 . Unless the @entity439 is expanding, however, we elect to perform coronay revascularization first, with resection and graft replacement of the @entity439 immediately after heparin reversal. Occlusive disease of the superficial femoral artery can be corrected immediately following aortocoronary bypass. Since the femoral and upper leg incisions have been performed, in certain cases it is convenient to complete the femoral popliteal bypass while the chest is being closed, thus saving a separate operation to correct the @entity432 .

title: Surgical correction of XXXX associated with lesions of the aorta ad its major branches.

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['arterial disease']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'postoperative stroke']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid arterial disease']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension', 'reduction of the systemic pressure']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm', 'abdominal aneurysm']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary arterial disease']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['femoral occlusive disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity543 :: ('MESH:D016893', 'Disease') :: ['carotid stenosis']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary arterial disease']


abstract: We had a two-month-old @entity1 with severe @entity1909 since birth. Her serum RAST to @entity2033 , Df and Dp were 1.06, 0.03 and 0.01 Ua/ml respectively. A Yorkshire terrier were kept at her mother's parents' home where the @entity1 had lived for a month since birth. Her @entity484 , which became markedly aggravated whenever she visited there, improved after the elimination of the @entity235 . We investigated the relationship between keeping @entity235 and @entity483 . We studied 368 @entity1 under the age of two years (211 @entity1 and 157 @entity1 ). Skin symptoms were graded globally mild, moderate or severe. Total serum IgE and specific antibody titer to @entity235 dander were measured. We asked them whether they kept @entity235 and specifically, where they kept @entity235 , outdoor, indoor, in their own house, or in their grandparents' house. 197 @entity1 had no contact with @entity235 , 90 @entity1 kept @entity235 outdoor and 81 @entity1 did indoor. The positive rate of RAST (> or = 0.7 Ua/ml) to @entity235 dander was 6.1%, 17.8% and 46.9% respectively in these three groups. There were strong statistical differences between three groups. On the other hand, among the 81 @entity1 who kept indoor, the RAST positive rates were almost same regarding where the @entity235 were kept, in their own house or their grandparents' house. Interestingly this difference happens only with @entity1 under the age of 3 months. @entity1 older than 4 months showed no significant differences in the positive RAST rates, whether they kept @entity235 indoor or outdoor. This suggests the sensitization occurs before the age of 3 months. Speaking of symptoms, @entity1 who kept @entity235 indoor showed significantly more severe symptoms than @entity1 who had no contact with @entity235 and @entity1 who kept @entity235 outdoor. There was no significant difference between the symptoms of @entity1 who had no contact with @entity235 and those of @entity1 who kept @entity235 outdoor. This implies the @entity1 's symptom will improve only by moving the @entity235 out of the house.

title: [Keeping XXXX indoor aggravates @entity483 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['girl', 'Patients', 'patients', 'patient', 'boys', 'girls']

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['infantile atopic dermatitis']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: OBJECTIVE: To assess sources of delay in referral to a specialist Urology clinic for @entity5 . METHODS: @entity1 with @entity5 seen during the period December 2002 to December 2007 were identified from the unit's database. Information regarding presentation, diagnosis and pattern of referral was retrieved from records. Delay was defined as the time between the @entity1 first noticing a @entity546 and date of first seeking medical advice, or additional time before being seen by a Urologist resulting from referral to another specialty. RESULTS: Of 100 @entity1 , with a median age of 54 years (range 2-81 years), 19% were initially referred to other specialties (Genitourinary Medicine-13%, Dermatology-4%, Plastics 2%). Initial referrals to Genito-urinary Medicine and Dermatology resulted in mean delays of 6 and 3.5 months respectively, whereas the mean duration for @entity1 to present to any medical practitioner from onset of symptoms was 5.8 months. Overall, 47% presented with locally advanced disease. CONCLUSION: Approximately one-fifth of @entity1 with @entity5 are first referred to specialties other than Urology. This sometimes delays diagnosis, potentially affecting overall prognosis. The major source of delay, however, results from @entity1 reluctance to seek medical advice. Thus, the greatest impact in this condition is likely to be achieved by increased public awareness and education.

title: Referrals into a dedicated British XXXX centre and sources of possible delay.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['penile cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity546 :: ('MESH:D004414', 'Disease') :: ['penile lesion']

answer: @entity5 :: (MESH:D009369,Disease) :: ['penile cancer']


abstract: INTRODUCTION: Diffusion tensor magnetic resonance (MR) imaging (DTI) can be used to characterize the microstructures of ordered biological tissues. This study was designed to assess histological features of @entity11 and surrounding brain tissues in @entity35 using DTI. METHODS: Three types of @entity5 , a 9L @entity3038 (n = 8), a F98 @entity11 (n = 5), and a @entity1 @entity463 xenograft (GBM22; n = 8) were incubated in @entity35 brains and underwent conventional MRI and DTI scanning using a 4.7-T animal MRI system. Fractional anisotropy (FA), isotropic apparent diffusion coefficient, parallel diffusivity (  //), and perpendicular diffusivity (     ), as well as histological features within several regions of interest were analyzed. RESULTS: All @entity5 masses consisted of low-FA central zones ( @entity5 center) and high-FA peripheral regions ( @entity5 rim). Histological examination revealed the existence of highly coherent @entity5 organizations (circular for 9L and F98 or radial for GBM22) in the @entity5 rims. There were higher apparent diffusion coefficient,      , and   // in the peritumoral @entity4 compared to the contralateral gray matter. There were significantly lower FA and higher       in the ipsilateral white matter than in the contralateral white matter for the GBM22 @entity5 , whereas there were no differences for the 9L and F98 @entity5 . Histologic examination showed GBM22 @entity5 infiltration into the ipsilateral damaged white matter. CONCLUSIONS: Quantitative analysis of DTI indices provides useful information for assessing @entity5 microstructure and @entity5 cell invasion into the adjacent gray matter and white matter.

title: Diffusion tensor magnetic resonance imaging of XXXX @entity11 models: a correlation study of MR imaging and histology.

entities_list: @entity3038 :: ('MESH:D018316', 'Disease') :: ['gliosarcoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas', 'glioma']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: @entity1381 ( @entity1381 ) has been associated with defective regulation of the alternative complement pathway. Although the use of plasma therapy is recommended, there is little consensus on the optimal treatment regimen. The outcome in many cases remains poor despite an improvement in our understanding of the pathology of @entity1381 . We have followed a female @entity1 with @entity1381 associated with heterozygous @entity4050 ( @entity4050 ) mutation ( @entity29004 ) over a period of 15 years. She has been plasma dependent since infancy and has subsequently progressed to @entity454 ( @entity454 ) requiring dialysis treatment. Despite @entity454 she still depends on regular plasma infusions to prevent @entity882 . The long-term treatment plan for this @entity1 is challenging. Renal transplantation in @entity1 with the @entity29004 mutation of the @entity4050 gene carries a high risk of failure due to recurrence of @entity1381 in the renal graft. Thus, the only available curative treatment seems to be combined liver-kidney transplantation, covered by intensive plasma therapy, which comes with a high risk of morbidity and mortality. Antibodies against key activating components of the complement cascade may provide a promising alternative therapeutic strategy in the future. Eculizumab, a monoclonal humanized anti-C5 antibody, has recently been shown to be effective and well-tolerated in @entity1 with @entity7965 by preventing complement-mediated lysis of affected erythrocytes. Treatment of our @entity1 with eculizumab is supported by recent reports on its successful use in two (pediatric and adult) @entity1 with complement-based @entity1381 .

title: Severe atypical HUS caused by @entity4050 XXXX --case presentation and review of treatment options.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity7965 :: ('MESH:D006457', 'Disease') :: ['paroxysmal nocturnal hemoglobinuria']

entities_list: @entity1381 :: ('MESH:D006463', 'Disease') :: ['aHUS', 'Atypical hemolytic uremic syndrome']

entities_list: @entity4050 :: ('3075', 'Gene') :: ['complement Factor H', 'CFH']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['ESKD', 'end stage kidney disease']

answer: @entity29004 :: (p|SUB|S|1191|L,ProteinMutation) :: ['S1191L']


abstract: Airway mucus forms the structural basis of the local innate immune defense mechanism. It is an integrated, active, viscoelastic gel matrix evolved to protect the exposed lung from physical, chemical, and pathological erosion. Exosomes are biologically active vesicles secreted by different cell types including epithelial, @entity1583 , and some @entity5 cells. They are also present in some biological fluids such as serum, urine, breast milk, and bronchoalveolar lavage fluid. In this study, we demonstrate for the first time that exosome-like vesicles with antiviral properties are present in @entity1 tracheobronchial epithelial (HTBE) cell culture secretions. These vesicles have been isolated by differential centrifugation and are characterized further by mass spectrometry, flow cytometry, immunoblotting, electron microscopy, and light-scattering methods. HTBE vesicles exhibited characteristic exosomal size (30-100 nm) and morphology (cup-shaped) with a buoyant density in sucrose of 1.12-1.18 g/ml. Biochemical characterization further revealed typical surface, cytoskeletal, and cytoplasmic proteins characteristic of exosomes, including the multivesicular and late endosomal membrane markers @entity27975 and @entity5775 . The presence of RNA was also observed. The epithelial mucins @entity2355 , @entity5088 , and @entity10224 also contributed to the vesicles' structure. Notably, alpha-2,6-linked @entity3167 was associated with these @entity3558 molecules and subsequent functional analysis showed that these vesicles have a neutralizing effect on @entity1 influenza virus, which is known to bind @entity3167 . Taken together, these findings suggest that airway epithelial cells release exosome-like vesicles and that these structures may be involved in diverse physiological processes in airway biology, including innate @entity33 .

title: Characterization of exosome-like vesicles released from XXXX tracheobronchial ciliated epithelium: a possible role in innate defense.

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['sialic acid']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal defense']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematopoietic']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: We report here the long-term survival case of advanced @entity418 treated with definitive chemoradiotherapy (CRT). A 61-year-old @entity1 visited our hospital because of a disturbance in her swallowing in September, 2003. She was diagnosed with a middle esophageal type 3 @entity5 , which was 9 cm in length by endoscopy. @entity957 was diagnosed by pre-operative endoscopic biopsy. CT revealed the @entity5 with direct invasion to the aorta, and multiple metastases of the lymph nodes(T4, N1, M0: Stage IVa). CRT(combination of @entity1487 and @entity1814 with 40 Gy of radiation)was administered. After the completion of CRT, the @entity5 size was remarkably reduced, but stenosis of the lumen of the esophagus remained partially. Therefore, we performed sub-total esophagectomy in February, 2004. A pathological complete response was diagnosed with no @entity189 cells evident in the resected specimen. Pathological therapeutic evaluation of the @entity418 was grade 3. The @entity1 had received no adjuvant chemotherapy, but she is alive and healthy now with no relapse of @entity189 for more than 8 years after operation.

title: [A case of advanced @entity418 revealed a pathological complete response and survived more than 8 years, treated by radiation therapy combined with @entity1814 and XXXX chemotherapy].

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['Squamous cell carcinoma']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity1814 :: ('MESH:C053989', 'Chemical') :: ['nedaplatin']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer']

answer: @entity1487 :: (MESH:D005472,Chemical) :: ['5-FU']


abstract: PURPOSE: This prospective study was designed to check the ideal time of surgical intervention by comparing the results of early elective laparoscopic sigmoid resection after an inflammatory attack with those of late elective resection during the @entity32 -free interval. METHODS: A total of 210 @entity1 (114 males) underwent laparoscopic resection for acute @entity4436 between 1999 and 2005. They were prospectively divided into two groups: Group I with an early elective sigmoid resection (5-8 days after initial antibiotic treatment); Group II in the @entity32 -free interval (4-6 weeks after initial hospitalization). RESULTS: There was no difference between the groups with regard to age (55.7 years), American Society of Anesthesiologists score (1.86), previous diseases, and extent of @entity32 . After surgery, 156 @entity1 (74.3 percent) were complication-free. There was a total of ten conversions (Group I, 9; Group II, 1; P<0.05). Minor complications developed in 42 @entity1 (abdominal wall abscess=24, @entity1944 =6, @entity1410 =9, urinary tract infection=2). Eight @entity1 in Group I (P<0.05) developed @entity834 . None of the @entity1 died. CONCLUSIONS: In the majority of @entity1 , laparoscopic sigmoid resection in @entity4436 can be performed without conversion. @entity1 who underwent surgery in the @entity32 -free interval had a lower complication rate than those submitted to early elective resection. In our @entity1 population, we were able to show that surgery in the @entity32 -free interval significantly reduces postoperative morbidity. It is thus preferable for @entity1 with @entity4436 to receive initial antibiotic treatment and then undergo late elective laparoscopic sigmoid resection.

title: What is the optimal time of surgical intervention after an acute attack of XXXX : early or late elective laparoscopic resection?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1944 :: ('MESH:D007410', 'Disease') :: ['intestinal atony']

entities_list: @entity834 :: ('MESH:D057868', 'Disease') :: ['anastomotic leaks']

entities_list: @entity4436 :: ('MESH:D004238', 'Disease') :: ['sigmoid diverticulitis']

answer: @entity4436 :: (MESH:D004238,Disease) :: ['sigmoid diverticulitis']


abstract: INTRODUCTION: @entity7860 is a rare @entity1200 with formation of pathognomonic antibodies against renal and pulmonary basement membranes. Cerebral involvement has been reported in several cases in the literature, yet the pathogenetic mechanism is not entirely clear. CASE PRESENTATION: A 21-year-old Caucasian @entity1 with @entity7860 and @entity454 presented with two generalized @entity410 after a period of mild @entity73 . Blood pressure and routine laboratory tests did not exceed the @entity1 's usual values, and examination of cerebrospinal fluid was unremarkable. Cerebral magnetic resonance imaging (MRI) revealed multiple cortical and @entity75 on fluid-attenuated inversion recovery sequences. Since antiglomerular basement membrane antibodies were found to be positive with high titers, plasmapheresis was started. In addition, @entity786 pulse therapy was given on day 13. @entity75 and @entity75 disappeared during this therapy, and antiglomerular basement membrane antibodies were significantly reduced. Previous immunosuppressive therapy was performed without @entity288 and terminated early after 3 months. The differential diagnostic considerations were @entity12513 and posterior reversible @entity75 syndrome. @entity1333 could be seen as an extrarenal manifestation of the underlying disease. Posterior reversible @entity75 syndrome, on the other hand, can be triggered by immunosuppressive therapy and may appear without a @entity101 crisis. CONCLUSION: A combination of central nervous system symptoms with a positive antiglomerular basement membrane test in a @entity1 with @entity7860 should immediately be treated as an acute exacerbation of the disease with likely cross-reactivity of antibodies with the choroid plexus. In our @entity1 , a discontinuous strategy of immunosuppressive therapy may have favored recurrence of @entity7860 .

title: Cerebral involvement in a @entity1 with XXXX due to shortened induction therapy: a case report.

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity12513 :: ('MESH:D020293', 'Disease') :: ['cerebral vasculitis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['Encephalopathy', 'MRI lesions', 'encephalopathy', 'subcortical lesions']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive disturbance']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['immunological disease']

entities_list: @entity7860 :: ('MESH:D019867', 'Disease') :: ["Goodpasture's disease"]

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']

answer: @entity7860 :: (MESH:D019867,Disease) :: ['Goodpasture's disease']


abstract: Correlations between genetic expression in @entity742 when dams were young (1 yr), middle-aged (2 and 3 yr), or older (older than 3 yr) were estimated with three-trait analyses for weight traits. Weights at birth ( @entity27466 ) and weaning (WWT) and ADG from birth to weaning were used. Numbers of observations were 7,731, 9,518, 9,512, and 9,201 for Columbia (COLU), Polypay (POLY), Rambouillet (RAMB), and Targhee (TARG) breeds of @entity742 , respectively. When averaged, relative estimates for WWT and ADG were similar across breeds. Estimates were variable across breeds. On average, direct heritability was greater when environment was young dams (.44 for @entity27466 and .34 for WWT) than when environment was dams of middle age or older (.24 and .28 for @entity27466 and .20 and .16 for WWT, respectively). Maternal heritability was greater when dams were middle-aged or older (.28 and .22 vs .18) for @entity27466 but was greater when dams were younger (.10 vs .05 and .04) for WWT. The estimates of genetic correlations for direct effects across age of dam environments averaged .32 for birth weight and averaged .70 for weaning weight. Average estimates of maternal genetic correlations across age of dam classes were .36 or less for both @entity27466 and WWT. Average estimates of correlations among maternal permanent environmental effects were .49 or less across age of dam classes. Total maternal effects accounted for .33 to .42 of phenotypic variance for @entity27466 and for .09 to .26 of phenotypic variance for WWT. The average estimates of genetic correlations between expressions of the same genotypes with different ages of dams suggest that measurements of @entity27466 of @entity742 with dams in young, middle, and older age classes should be considered to be separate traits for genetic evaluation and that for WWT measurements with young age of dam class and combined middle and older age of dam classes should be considered to be separate traits for genetic evaluation.

title: Genotypic expression with different ages of dams: III. Weight traits of XXXX .

answer: @entity742 :: (9940,Species) :: ['sheep']


abstract: BACKGROUND: @entity111 is a common and bothersome problem in 30-50% of hemodialysis @entity1 . The aim of this study was to determine the effect of @entity2682 , 100 mg/three times a week (after each hemodialysis session), on @entity1381 . STUDY DESIGN: @entity1 older than 18 years who had undergone hemodialysis for more than three months were enrolled in this double-blind clinical trial. They had experienced @entity111 refractory to antihistamines for at least two weeks. The @entity1 were assigned to receive @entity2682 100 mg following hemodialysis for a period of four weeks, and after a washout week, they received the placebo for another four weeks. They were asked to evaluate the severity of their @entity111 using a visual analogue scale (VAS). The reduction of @entity111 >or= 50% was accepted as the response. RESULTS: The mean @entity111 score reached 6.44 +/- 8.4 (p < 0.0001), 15 +/- 11.2 (p < 0.001), and 81.11 +/- 11.07 (p < 0.001) during @entity2682 , washout, and placebo periods, respectively. No significant correlation was found between age, sex, duration of dialysis, underlying @entity551 and the @entity2682 effect. CONCLUSION: @entity2682 is an effective agent in treating @entity1381 .

title: @entity2682 and XXXX in hemodialysis @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2682 :: ('MESH:C040029', 'Chemical') :: ['Gabapentin', 'gabapentin']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['Pruritus', 'pruritus']

entities_list: @entity1381 :: ('MESH:D006463', 'Disease') :: ['uremic pruritus']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['diseases, and systolic and diastolic blood pressures']

answer: @entity1381 :: (MESH:D006463,Disease) :: ['uremic pruritus']


abstract: BACKGROUND: Many techniques have been developed to soften the cervix to reduce complications following surgical dilatation. @entity1420 inhibits myometrial contractility and its secretion during pregnancy ensures cervical competence. We used the @entity1420 antagonist @entity3927 as a cervical ripening agent and evaluated its effect prior to office hysteroscopy. METHODS: Fifty-eight healthy non-pregnant @entity1 aged 18-50 were studied in a randomized double-blind study. They received @entity3927 (200 mg) or placebo 30 h prior to hysteroscopy. A Hegar test was performed prior to drug administration and again before hysteroscopy. A visual analogue @entity158 scale was used to assess @entity158 . RESULTS: Medical history, physical examination and blood tests were similar in both groups, except for serum @entity1420 which was higher in the study group. Hegar measurement prior to drug ingestion was similar in both groups and after a mean time of 30.3 h increased in both groups. Neither the DeltaHegar measurement nor the @entity158 scale was different in the two groups. There was also no effect of the high @entity1420 levels. CONCLUSIONS: Unlike its dramatic effect in the pregnant uterus, @entity3927 administered 30 h prior to hysteroscopy was not effective in ripening the cervix of non-pregnant @entity1 .

title: XXXX does not induce cervical softening in non-pregnant @entity1 .

entities_list: @entity3927 :: ('MESH:D015735', 'Chemical') :: ['mifepristone']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone', 'Progesterone']

answer: @entity3927 :: (MESH:D015735,Chemical) :: ['Mifepristone']


abstract: Combination therapy between two immunomodulators used for treatment of chronic @entity1956 was explored based on reported therapeutic efficacy of interferon-alpha, and @entity10136 -alpha1 as monotherapeutic agents to determine if combination therapy was superior to interferon alone. This double-blinded, randomized, placebo-controlled trial compares the addition of @entity10136 -alpha1, 1.6 microg taken three times per week (combination therapy) or @entity10136 placebo (monotherapy) to lymphoblastoid interferon (Wellferon), 5 million international units (MIU) taken three times per week, for 24 weeks. Entry criteria included positive @entity1956 e antigen (HBeAg); @entity493 aminotransferease (ALT) > or = 1.5 x upper normal limit, but < or = 10 x upper normal limit; positive @entity97 DNA; absence of @entity82 ; treatment naivety and no co-morbid factors. A total of 98 HBeAg-positive @entity1 were recruited, of which 48 were randomized to combination therapy and 50 to monotherapy. The primary endpoint was the loss of HBeAg at 72 weeks. The secondary endpoints were HBeAg seroconversion, normalization of ALT, loss of @entity97 DNA and improvement in histology. The HBeAg loss was 45.8% and 28.0% for combination therapy and monotherapy, respectively (difference, 17.8%; 95% CI -1.2%-35.3%, P = 0.067). There was a trend towards HBeAg loss when using combination therapy. There were also no statistically significant differences between the different therapies with respect to the secondary endpoints of HBeAg seroconversion, changes in histology, normalization of ALT or loss of @entity97 DNA. In conclusion, this trial showed a 17.8% improvement in HBeAg loss rates using combination therapy over interferon monotherapy. This could clinically indicate a potential important difference that would need confirmation in subsequent trials.

title: A randomized, placebo-controlled trial of XXXX -alpha1 and lymphoblastoid interferon for HBeAg-positive chronic @entity1956 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity1956 :: ('MESH:D006509', 'Disease') :: ['hepatitis B']

entities_list: @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine']

answer: @entity10136 :: (MESH:D013947,Chemical) :: ['thymosin']


abstract: OBJECTIVES: Inflammatory @entity121 are a group of idiopathic, heterogeneous @entity262 affecting predominantly skeletal muscles, though they can also involve the skin and internal organs. The association between @entity5 and @entity5442 , particularly @entity6017 , which is termed @entity5 -associated @entity5442 (CAM), has been reported in the medical literature. A newly described autoantibody to a 155-kDa nuclear protein, identified as transcription intermediary factor 1-gamma ( @entity35837 -y), has proven useful for @entity5 screening in @entity1 with @entity6017 . MATERIAL AND METHODS: Based on our database of laboratory results, between November 2014 and January 2016, we found 80 @entity1 with a positive autoimmune @entity5442 immunoblot profile. RESULTS: Eleven of 80 @entity1 revealed the presence of anti- @entity35837 -y antibodies: 8 @entity1 and 3 @entity1 with average age 54.2 years. @entity6017 ( @entity6017 ) was diagnosed in 6 cases, @entity6558 in 1 case, @entity5442 limited to ocular muscles and @entity5925 in 1 case each, and undifferentiated connective tissue disease in 2 cases. @entity5 was found in 4 cases. All of those @entity1 had @entity6017 . The average time between @entity6017 and diagnosis of @entity5 was 7.5 months (from 1 to 18 months). CONCLUSIONS: The association between @entity5 and @entity5442 , particularly @entity6017 , is well known, and @entity5 screening should be obligatory in such @entity1 . So far there is no consensus as to the method or frequency with which @entity1 with an idiopathic @entity5442 should be tested to rule out @entity5 . Detection of anti- @entity35837 -y antibodies in @entity1 with @entity6017 gives the clinicians the very important suggestion of CAM. It seems reasonable that these @entity1 should have more detailed and often repeated differential diagnostics.

title: Clinical characteristics of patients with anti- XXXX -y antibodies.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity6017 :: ('MESH:D003882', 'Disease') :: ['dermatomyositis', 'Dermatomyositis', 'DM']

entities_list: @entity5442 :: ('MESH:D009220', 'Disease') :: ['inflammatory myopathy', 'myositis', 'idiopathic inflammatory myopathies']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Neoplasm', 'cancer', 'neoplasm']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic diseases']

entities_list: @entity5925 :: ('MESH:D012206', 'Disease') :: ['rhabdomyolysis']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathies']

entities_list: @entity6558 :: ('MESH:D017285', 'Disease') :: ['polymyositis']

answer: @entity35837 :: (8805,Gene) :: ['TIF1']


abstract: The aim of previous research into the causes of @entity56 , including @entity565 was mostly to identify potential risk factors in the environment. No major risk factors have been identified, however. Over the past 10 years, focus has, therefore, more been directed towards protective factors that could enhance the development of tolerance to allergens which were previously encountered early in life, but are now lost in modern affluent societies. In particular, the role of childhood @entity281 has been discussed, but so far these studies have not been conclusive. Recent epidemiological studies and experimental research suggest that the microbial environment and exposure to microbial products in infancy modifies immune responses and enhances the development of tolerance to ubiquitous allergens. The intestinal microflora may play a particular role in this respect, as it is the major external driving force in the maturation of the immune system after birth, and animal experiments have shown it to be a prerequisite for normal development of oral tolerance. Recent studies have shown differences in the composition of the microflora between healthy and allergic @entity1 in countries with a high and low prevalence of @entity566 and between healthy and allergic @entity1 within such countries. These differences are apparent within the first week of life and thus precede clinical symptoms. The use of live microorganisms that might be beneficial to health has a long tradition and the safety is well documented. Very recently, several prospective intervention studies, modifying the gut flora from birth have yielded encouraging results and may suggest a new mode of primary prevention of @entity566 in the future.

title: Effects of intestinal microflora and the environment on the development of @entity565 and XXXX .

entities_list: @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy', 'allergies']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic diseases']

answer: @entity566 :: (MESH:D006967,Disease) :: ['allergy']


abstract: @entity2085 has been proposed as a way to leverage the genetic differences found in @entity5 cells to affect their selective killing. Cohesins, which tether sister chromatids together until anaphase onset, are mutated in a variety of @entity5 types. The elucidation of synthetic lethal interactions with cohesin mutants therefore identifies potential therapeutic targets. We used a cross-species approach to identify robust negative genetic interactions with cohesin mutants. Utilizing essential and non-essential mutant synthetic genetic arrays in @entity375 , we screened genome-wide for genetic interactions with hypomorphic mutations in cohesin genes. A somatic cell proliferation assay in @entity2199 demonstrated that the majority of interactions were conserved. Analysis of the interactions found that cohesin mutants require the function of genes that mediate replication fork progression. Conservation of these interactions between replication fork mediators and cohesin in both @entity375 and @entity2199 prompted us to test whether other replication fork mediators not found in the @entity375 were required for viability in cohesin mutants. PARP1 has roles in the DNA damage response but also in the restart of stalled replication forks. We found that a hypomorphic allele of the @entity2199 SMC1 orthologue, him-1(e879), genetically interacted with mutations in the orthologues of PAR metabolism genes resulting in a reduced brood size and somatic cell defects. We then demonstrated that this interaction is conserved in @entity1 cells by showing that @entity12982 inhibitors reduce the viability of cultured @entity1 cells depleted for cohesin components. This work demonstrates that large-scale genetic interaction screening in @entity375 can identify clinically relevant genetic interactions and suggests that @entity12982 inhibitors, which are currently undergoing clinical trials as a treatment of homologous recombination-deficient @entity5 , may be effective in treating @entity5 that harbor cohesin mutations.

title: XXXX of cohesins with PARPs and replication fork mediators.

entities_list: @entity2085 :: ('MESH:D020964', 'Disease') :: ['Synthetic lethality']

entities_list: @entity2199 :: ('6239', 'Species') :: ['C. elegans', 'Caenorhabditis elegans']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers']

entities_list: @entity375 :: ('4932', 'Species') :: ['yeast', 'Saccharomyces cerevisiae']

answer: @entity2085 :: (MESH:D020964,Disease) :: ['Synthetic lethality']


abstract: Conservative surgery with adjuvant chemotherapy has made the preservation of fertility even in @entity1 with @entity1442 . The increase in cure rate has shifted to research for the long term menstrual reproductive and gynecologic outcome in these @entity1 . The current study is retrospective for 25 cases of @entity43 from January 2006 to January 2011, at El Hussian and Sayed Galal University Hospitals. The uterus and contralateral ovary were retained to preserve ovarian function with or without chemotherapy, followed up for two years. The mean age of most @entity1 ranged from 15-28 years (average 21.5 years). According to International Federation of Gynecology and Obstetrics, the histological subtypes were @entity5000 (40%). Five @entity44 (20%), three @entity2970 (12%), four @entity2971 (16%) three @entity5 (12%). Stage I: @entity5 15 cases (60%), Stage II: @entity5 one case (4%), @entity5 6 cases (24%), Stage IV @entity5 3 cases (12%). Adjuvant chemotherapy was administered to 15 cases 60% and followed up for two years. There were two recurrences, one died at 7th day postoperative of massive @entity1151 with past history of D.V.T, five healthy live births in the chemotherapy group without @entity600 , and one @entity249 case 4%.

title: Conservative surgery in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian malignant germ cell tumor']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity44 :: ('MESH:D013724', 'Disease') :: ['immature teratoma']

entities_list: @entity2971 :: ('MESH:D009373', 'Disease') :: ['mixed germ cell tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'embryonic cell tumours', 'Stage III tumors']

entities_list: @entity2970 :: ('MESH:D018240', 'Disease') :: ['endodermal sinus tumor']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['birth defects']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease']

entities_list: @entity5000 :: ('MESH:D004407', 'Disease') :: ['ten dysgerminoma']

answer: @entity43 :: (MESH:D010051,Disease) :: ['malignant ovarian germ cell tumours']


abstract: UNASSIGNED: Lack of support is reported as a key reason for early breastfeeding cessation. While @entity17744 ( @entity17744 ) is a recommended intervention to increase breastfeeding rates, a number of studies identify that engagement with @entity17744 is problematic. Due to paucity of research in this area, this study explores why breastfeeding @entity1 do not access @entity17744 in South-West England. Utilising a constructionist grounded theory approach, 33 @entity1 ( @entity1 (n   =   13), health professionals (n   =   6) and peer supporters (n   =   14)) participated in a semi-structured interview (n   =   22) or focus group (n   =   11). Analysis involved open coding, constant comparisons and focussed coding. One core category and three main themes explicating non-access were identified. The core category concerns @entity1 's experiences of pressure and judgement around their feeding decisions within a dichotomous landscape of @entity1 feeding language and support. Theme one, 'place and space of support', describes the contrast between perceived pressure to breastfeed and a lack of adequate and appropriate support. Theme two, 'one way or no way', outlines the rules-based approach to breastfeeding adopted by some health professionals and how @entity1 avoided @entity17744 due to anticipating a similar approach. Theme three, 'it must be me', concerns how lack of embodied insights could lead to 'breastfeeding failure' identities. A background of dichotomised language, pressure and moral judgement, combined with the organisation of post-natal care and the model of breastfeeding adopted by health professionals, may inhibit @entity1 's access to @entity17744 . A socio-cultural model of breastfeeding support providing clear messages regarding the value and purpose of @entity17744 should be adopted.

title: Pressure and judgement within a dichotomous landscape of XXXX feeding: a grounded theory study to explore why breastfeeding @entity1 do not access peer support provision.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'infant']

entities_list: @entity17744 :: ('MESH:C565501', 'Disease') :: ['breastfeeding peer support', 'BPS']

answer: @entity1 :: (9606,Species) :: ['infant']


abstract: During a 5-year period from 1979 to 1983 all @entity1 in Denmark with metastatic non-seminomatous and extragonadal germ cell @entity5 were treated with 6 cycles of @entity900 , @entity5713 , and @entity1732 ( @entity7297 ). Thirty-nine @entity1 referred to the Finsen Institute accepted a follow-up examination of side-effects 3.5-9 years after chemotherapy. @entity8 consisted of an irreversible decrease in glomerular filtration rate (GFR) in 47% of the @entity1 , while the decrease in GFR was fully reversible in 23%. Significant @entity358 was observed in smokers and consisted of an irreversible decrease in @entity1223 diffusion capacity to median 72% of the predicted value. @entity2359 was the most pronounced long-term side-effect. Nearly all @entity1 had a @entity1897 probably caused by @entity528 . A central conduction defect was observed in 88% of the @entity1 by measuring auditory brain-stem potentials. Irreversible @entity2198 was induced in 39% of the @entity1 . @entity129 was found in 36% of the examined @entity1 , including 2 @entity1 with @entity323 . Half of the @entity1 revealed @entity2407 ( @entity2407 ), and the mechanism underlying this side-effect was found to be hyperreactivity of the central sympathetic nervous system. Vascular @entity137 was found only in terminal arterioles and was not responsible for @entity2407 . @entity7297 treatment caused @entity6660 and a subclinical Leydig cell dysfunction in the majority of @entity1 . @entity3893 was observed in 27% of the @entity1 . Six @entity1 had @entity101 and this was not related to @entity8 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Late-effects after treatment for germ-cell XXXX with @entity900 , @entity5713 , and @entity1732 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2198 :: ('MESH:D006316', 'Disease') :: ['high-frequency hearing loss']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['Renal toxicity', 'renal impairment']

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['Parasympathetic nerve dysfunction']

entities_list: @entity323 :: ('MESH:D007172', 'Disease') :: ['impotence']

entities_list: @entity1223 :: ('MESH:D002248', 'Chemical') :: ['carbon monoxide']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2359 :: ('MESH:D020258', 'Disease') :: ['Neurotoxicity']

entities_list: @entity2407 :: ('MESH:D011928', 'Disease') :: ['RP', "Raynaud's phenomenon"]

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral sensory neuropathy']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity3893 :: ('MESH:D053713', 'Disease') :: ['Azoospermia']

entities_list: @entity6660 :: ('MESH:D009845', 'Disease') :: ['low sperm counts']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['axonal degeneration']

entities_list: @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: The authors had previously shown that the subcutaneous administration of @entity205 (CsA) resulted in an impairment of spermatogenesis. @entity251 levels declined and gonadotropin levels increased, suggesting that CsA primarily affects the synthesis and secretion of @entity251 . In this study, the authors attempted to determine whether the exogenous administration of @entity251 would maintain spermatogenesis in animals treated with a very high dose of CsA. Sexually mature, male @entity35 were treated subcutaneously with CsA (40 mg/kg per day) alone, or in combination with @entity3033 (TP; 2 and 5 mg/d per @entity35 ), for 14 days. As expected, @entity870 reduced the body and reproductive organ weights and the levels of serum @entity251 , while elevating the levels of follicles-stimulating hormone (FSH) and luteinizing hormone (LH). Quantitative analysis of spermatogenesis revealed a decline in all the different types of germ cells in tubules at stage VII of the cycle of the seminiferous epithelium. Administration of TP in 2 and 5 mg/d per @entity35 doses restored the body and reproductive organ weights and the circulating levels of FSH. The serum levels of LH were below the assay's minimum level of detectability. Analysis of spermatogenesis revealed a dose-dependent increase in the germ cell counts after the administration of 2 and 5 mg of TP. The circulating levels of CsA were also significantly reduced after TP administration. These results revealed that CsA-induced alteration in spermatogenesis can be prevented by the exogenous administration of @entity251 .

title: Quantitative maintenance of spermatogenesis in @entity205 -treated @entity35 by exogenous administration of XXXX .

entities_list: @entity3033 :: ('MESH:D043343', 'Chemical') :: ['testosterone propionate']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone', 'Testosterone']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats']

answer: @entity3033 :: (MESH:D043343,Chemical) :: ['testosterone propionate']


abstract: OBJECTIVES: The prevalence of @entity31 ( @entity31 ) differs by country, which is likely due to differences in genetic factors among ethnicities. Moreover, the prevalence of pediatric @entity31 with a @entity4310 ( @entity4310 ) is 4.1% in Japanese @entity1 ; its clinical course begins at an early age and is more severe. Recently, a genome-wide association study identified 3 new susceptibility loci for adult Japanese @entity1 with @entity31 . METHODS: To assess the effects of @entity4310 in @entity1 with @entity31 , 60 @entity1 were enrolled. Age at diagnosis, clinical features of the initial symptoms, and family structure were assessed in @entity1 with and without an @entity4310 . The 3 new loci were examined in @entity1 who provided informed consent. RESULTS: Of the @entity1 with @entity31 , 10 (16.7%) had an @entity4310 involving first-degree relatives, including 7 mothers, 1 father, and 2 sisters. There was a trend toward a younger age at onset in the positive @entity4310 group. There were, however, no significant differences in the clinical characteristics of the @entity1 regardless of @entity4310 . From the genomic analyses, there were significant differences in the polymorphisms of the @entity11751 ( @entity11751 ) between those with and without an @entity4310 . CONCLUSIONS: Although the etiology of @entity31 remains unknown, there were no observed relation between clinical symptoms and @entity4310 . @entity11751 may, however, contribute to the pathogenesis of @entity31 in Japanese individuals with an @entity4310 .

title: Assessment of the Family History of XXXX With @entity31 at a Single Center in Japan.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity11751 :: ('1811', 'Gene') :: ['solute carrier family 26, member 3', 'SLC26A3']

entities_list: @entity4310 :: ('MESH:D009386', 'Disease') :: ['FH', 'family history']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: @entity882 ( @entity882 ) is a pathophysiological syndrome caused by platelet-activating antibodies that recognize @entity18042 /heparin complexes. The abrupt onset of @entity882 following intravenous bolus heparin is known as an acute systemic reaction. Clinical features of this type of @entity882 may be similar to those of common complications during hemodialysis. The aim of the study was to identify whether the clinical features of the acute systemic reaction are caused by @entity882 or dialytic complications. Twenty-seven dialytic @entity1 who had @entity882 and clinical features of an acute systemic reaction were enrolled out of 202 @entity882 -suspected @entity1 . Thirteen @entity1 had @entity882 confirmed due to the presence of positive functional and immunoassays. Eight of the thirteen @entity1 presented with acute systemic reactions due to @entity882 . The most common symptom of acute systemic reaction was @entity1353 . The other nineteen @entity1 , involving both @entity882 and non- @entity882 @entity1 , had dialysis-complicated ASR. The major feature of the acute systemic reaction in hemodialysis was @entity551 and its relevant symptoms. An immunoassay for the detection of IgG antibodies against @entity18042 /heparin complexes ( @entity882 ) showed the wide-range linearity of the calibration curve by employing three concentrations of recombinant mouse monoclonal antibodies for @entity18042 /heparin complexes. The results are expressed as micrograms of IgG in one milliliter. Significantly high levels in thirteen @entity882 @entity1 were compared with levels in fourteen non- @entity882 @entity1 . The highest median of 1,530  g/ml (IQR: 3,267-813) was obtained in the presence of @entity882 associated with an acute systemic reaction. In @entity882 @entity1 who did not show characteristics of an @entity882 -derived acute systemic reaction, the median was 339  g/ml (1,178-834). Despite showing a positive ELISA, nine non- @entity882 @entity1 without any platelet-activating antibodies showed a value of 97  g/ml (166-56). The lowest median of 8.3  g/ml (11-6) was in non- @entity882 @entity1 with a negative ELISA. In conclusion, measurements of @entity882 -specific antibodies can facilitate an appropriate estimation in hemodialysis @entity1 of whether the clinical features of an acute systemic reaction are caused by @entity882 or dialytic complications.

title: Clinical evaluation of acute systemic reaction and detection of IgG antibodies against @entity18042 /heparin complexes in hemodialysis XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['Heparin-induced thrombocytopenia', 'HIT', 'HIT-IgG', 'thrombocytopenia']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: In order to find factors associated with @entity204 due to the Great Hanshin-Awaji earthquake, we conducted a descriptive epidemiological and a case-control study. METHODS: The study area was Nishinomiya city. Earthquake mortality was calculated by age group, sex and the degree of @entity16 . Cases in the case-control study included all 1,104 earthquake-caused @entity204 . Randomly selected survivors living in the same neighborhood and matching sex, age, and the degree of @entity16 were used as controls. Seven kinds of information about subject's health and welfare on January 16, one dey before the earthquake, were used for analysis. RESULTS: The likelihood of earthquake-caused mortality steadily increased after 50 years of age. Mortality among @entity1 who lived in completely destroyed dwellings was much higher than that among @entity1 who lived in intact or partially-destroyed dwellings. In the case-control study, a significant risk factor for @entity204 was @entity717 (odds ratio (OR) = 1.9; 95% confidence interval (95% C.I.), 1.0 to 3.34). When the analysis was limited to those who lived in intact or partially-destroyed dwellings, the odds ratio of @entity717 increased to 5.6 (95% C.I., 1.6 to 19.8). CONCLUSIONS: The most important risk factors were age and degree of @entity16 . @entity717 was suggested as a risk factor.

title: [Factors associated with XXXX in the Great Hanshin-Awaji Earthquake, 1995].

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['physical disability', 'Physical disability']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['damage to dwelling']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['earthquake deaths', 'earthquake death', 'deaths']

answer: @entity204 :: (MESH:D003643,Disease) :: ['earthquake deaths']


abstract: The tick bite transmitted @entity3001 is one of the most common antropozoonosis, about 10 000 new @entity281 are reported in Hungary each year. The progress and clinical presentation can vary, and @entity2401 can occur in later stages. A serologically verified @entity3001 caused @entity3354 degree @entity713 in young male presenting with @entity1163 . Based on the tick-bites mentioned a few weeks prior to hospital admission, @entity2401 was considered with the administration of antibiotics and monitor observation. Typical @entity272 were not recognized and laboratory findings showed no pathology. An electrophysiological study recorded a predominant supra-His @entity713 . Total regression of conduction could be detected later and the serological tests established an underlying @entity3001 . Currently no definite treatment recommendation is available for the potentially reversible @entity2401 . The tick bite seemed to be the key on our way to diagnosis; however, serological tests proved the disease to be older than one year. A detailed medical history and serological tests are essential in identifying the cause and pacemaker implantation can be avoided.

title: [Acute @entity713 in chronic XXXX ].

entities_list: @entity3001 :: ('MESH:D008193', 'Disease') :: ['Lyme disease']

entities_list: @entity713 :: ('MESH:D054537', 'Disease') :: ['atrioventricular block']

entities_list: @entity1163 :: ('MESH:D013575', 'Disease') :: ['presyncope']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin lesions']

entities_list: @entity2401 :: ('MESH:D009205', 'Disease') :: ['Lyme carditis', 'carditis']

answer: @entity3001 :: (MESH:D008193,Disease) :: ['Lyme disease']


abstract: OBJECTIVE: To identify clinical and imaging features at presentation that might predict long-term outcome in @entity1 with mild mesial @entity1315 (mMTLE), which is defined by at least 24 @entity410 -free months with or without antiepileptic medication. METHODS: In the setting of a prospective, population-based, longitudinal cohort study, we followed up 101 @entity1 , all with mMTLE at enrolment. By protocol, @entity1 underwent clinical evaluation every 3-12 months. Independent t test, Mann-Whitney test, or   (2) test was used for comparing 2 groups. The incidence rate of refractory MTLE (rMTLE) was expressed as number of cases every 100 @entity1 -years. RESULTS: After a mean follow-up of 12.2    3.7 years, 16 @entity1 dropped out and 85/101 (mean age 46.5    13.3 years) were available for the present analysis. Of these, 64/85 (75%) @entity1 remained @entity410 -free and 21/85 (25%) became refractory (rMTLE), the latter corresponding to 2.0 cases per 100 @entity1 per year. @entity1 with rMTLE showed a longer duration of @entity302 (p < 0.001), earlier age at @entity302 onset (p = 0.006), more frequent febrile @entity410 (p = 0.02), and @entity131 ( @entity131 ) at MRI (p = 0.004) as compared to those with mMTLE. CONCLUSIONS: mMTLE is a syndrome representing the mildest form of the wide spectrum of MTLE. Earlier age at onset, history of febrile @entity410 , longer duration of @entity302 , and the presence of @entity131 on MRI predict a worse outcome.

title: Long-term outcome of mild mesial XXXX : A prospective longitudinal cohort study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'person', 'persons']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'convulsions']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['hippocampal sclerosis', 'HS']

entities_list: @entity1315 :: ('MESH:D004833', 'Disease') :: ['temporal lobe epilepsy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

answer: @entity1315 :: (MESH:D004833,Disease) :: ['temporal lobe epilepsy']


abstract: Recent data challenge the relevance of the @entity995 pathway to @entity5 based on @entity995 inactivation, at least in @entity0 . To obtain information on the actual role of the components of the @entity995 pathway in @entity5 progression we decided to investigate whether their quantitative changes were associated with variations in the level of @entity995 phosphorylation in @entity1 @entity0 . A series of 68 @entity1 primary @entity0 was studied. Five cases were excluded from the study due to their lack of @entity995 expression. In the remaining 63 cases the expression of @entity4910 , @entity8985 , cyclin E, and @entity986 mRNA was assessed by real-time RT-PCR. The level of @entity995 phosphorylated protein (ppRB) and @entity5438 expression was immunohistochemically analyzed by measuring the percentage of stained cells (labeling index, @entity3162 ). Cell proliferation rate was measured by Ki67 @entity3162 evaluation. The ppRB @entity3162 ranged from 5.2 to 73.8 and, as expected, was strongly related to the Ki67 @entity3162 (r=0.80; p<0.001). The expression of @entity4910 mRNA, expressed in arbitrary units (a. u.), ranged from 1.15 to 123.0 and was inversely related to the ppRB @entity3162 (p=0.021) and Ki67 @entity3162 (p<0.001). Neither the @entity8985 (range from 0.07 to 1.13 a. u.) nor the cyclin E (range from 0.13 to 9.27 a. u.) mRNA expression was significantly associated with the ppRB @entity3162 (p=0.962 and p=0.103, respectively). Cyclin E was related to Ki67 @entity3162 (p=0.022). Both @entity986 mRNA (range from 0.01 to 0.60 a. u.) and @entity5438 ( @entity3162 from 0.0 to 73.1) values were inversely related to the ppRB @entity3162 (p=0.022 and p=0.014, respectively). @entity4910 , @entity8985 , and cyclin E mRNA expressions were not significantly related to one another. In @entity1 primary @entity0 , the expression levels of the factors known to facilitate the cell cycle progression by @entity995 protein phosphorylation were not positively related to ppRB- @entity3162 . Pathological increases of cyclin D, @entity8985 , and cyclin E are very likely associated with other biological functions other than their well-established action on cell cycle progression.

title: Controversial relationship between the expression of the @entity995 pathway components and XXXX protein phosphorylation in @entity1 @entity0 .

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'breast cancer', 'breast tumors', 'breast carcinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

answer: @entity995 :: (MESH:D012175,Disease) :: ['RB']


abstract: BACKGROUND: There is a move toward finding clinically useful "phenotypes" in community-acquired @entity55 : groups of @entity1 displaying distinct clinical characteristics, microbiology, and prognosis. @entity1174 is an intuitive clinical phenotype; however, to date there are no recognized diagnostic criteria, and data regarding outcomes in suspected @entity1173 are limited. METHODS: An observational study of 1348 @entity1 hospitalized with community-acquired @entity55 in the United Kingdom examined both short- and long-term outcomes for @entity1 at risk of @entity1174 . @entity1 were defined as "at risk" in the presence of chronic @entity16 , @entity1208 and @entity1282 , @entity73 , or witnessed @entity1173 . The primary outcome was 30-day mortality. Secondary outcomes included 1-year mortality, readmissions, and recurrent @entity55 within 1 year. RESULTS: Some 13.8% of the cohort were classified as "at risk of @entity1173 ." These @entity1 were older (median age, 74 years [interquartile range, 60-84] vs 66 years [interquartile range, 49-77]; P < .0001) and more likely to have comorbidities ( @entity409 11.3% vs 3.7%, P < .0001; @entity712 28% vs 17.1%, P = .0004; and @entity64 26.9% vs 9.5%, P < .0001). @entity1 at risk of @entity1174 had a poorer short-term outcome (30-day mortality 17.2% vs 7.7%, P < .0001), but after adjusting for their greater severity of illness and comorbidities this difference was not significant (odds ratio 1.05; 95% confidence interval [CI], 0.63-1.76; P = .8). However, @entity1 with @entity1173 risk factors were at greater risk of poor long-term outcomes with increased 1-year mortality (hazard ratio [HR], 1.73; 95% CI, 1.15-2.58), increased risk of rehospitalization (HR, 1.52; 95% CI, 1.21-1.91), and a strong association with recurrent admissions with @entity55 (HR, 3.13; 95% CI, 2.05-4.78) after multivariable adjustment. CONCLUSIONS: Using risk factors to identify @entity1 at risk of @entity1174 identifies a distinct clinically useful phenotype of @entity1 with greater severity of disease and poorer long-term outcomes.

title: Risk factors for @entity1173 in community-acquired XXXX : analysis of a hospitalized UK cohort.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired conscious level, vomiting']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic disorders']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['chronic liver disease']

entities_list: @entity1174 :: ('MESH:D011015', 'Disease') :: ['aspiration pneumonia', 'Aspiration pneumonia']

entities_list: @entity1208 :: ('MESH:D004935', 'Disease') :: ['esophageal disorders']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

entities_list: @entity1173 :: ('MESH:D053120', 'Disease') :: ['aspiration']

answer: @entity55 :: (MESH:D011014,Disease) :: ['pneumonia']


abstract: AIM: The aim of this study was to evaluate (a) the differences between @entity1 and @entity1 in symptom profile, allocated life support level (LSL), and presence of @entity583 ( @entity583 ), life-threatening condition (LTC), or @entity204 and (b) whether a computer-based decision support system could improve the allocation of LSL. @entity1 : All @entity1 in G  teborg, Sweden, who called the dispatch center because of @entity662 during 3 months (n = 503) were included in this study. METHODS: Age, sex, and symptom profile were background variables. Based on these, we studied allocation of LSL by the dispatchers and its relationship to @entity583 , LTC, and @entity204 . All evaluations were made from a sex perspective. Finally, we studied the potential benefit of using a statistical model for allocating LSL. RESULTS: The advanced life support level (ALSL) was used equally frequently for @entity1 and @entity1 . There was no difference in age or symptom profile between @entity1 and @entity1 in relation to allocation. However, the allocation of ALSL was predictive of @entity583 and LTC only in @entity1 . The sensitivity was far lower for @entity1 than for @entity1 . When a statistical model was used for allocation, the ALSL was predictive for both @entity1 and @entity1 . Using a separate model for @entity1 and @entity1 respectively, sensitivity increased, especially for @entity1 , and specificity was kept at the same level. CONCLUSION: This exploratory study indicates that @entity1 would benefit most from the allocation of LSL using a statistical model and computer-based decision support among @entity1 who call for an ambulance because of acute @entity662 . This needs further evaluation.

title: Does sex influence the allocation of life support level by dispatchers in acute XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

answer: @entity662 :: (MESH:D002637,Disease) :: ['chest pain']


abstract: OBJECTIVE: The aim of this study was early prediction of @entity1469 (GTN) after evacuation of high-risk mole, by comparison of @entity1 chorionic gonadotrophin ( @entity1465 ) regression rates. STUDY DESIGN: Fifty @entity1 with a high-risk mole initially and spontaneously regressing after molar evacuation were selected from January 1, 1996 to May 31, 2010 (spontaneous regression group). Fifty @entity1 with a high-risk mole initially and progressing to @entity1469 after molar evacuation were selected ( @entity1469 group). @entity1465 regression rates represented as @entity1465 /initial @entity1465 were compared between the two groups. The sensitivity and specificity of these rates for prediction of @entity1469 were assessed using receiver operating characteristic curves. Multivariate analyses of associations between risk factors and @entity1469 progression were performed. RESULTS: The mean regression rate of @entity1465 between the two groups was compared. @entity1465 regression rates represented as @entity1465 /initial @entity1465 (%) were 0.36% in the spontaneous regression group and 1.45% in the @entity1469 group in the second week (p=0.003). Prediction of @entity1469 by @entity1465 regression rate revealed a sensitivity of 48.0% and specificity of 89.5% with a cut-off value of 0.716% and area under the curve (AUC) of 0.759 in the 2nd week (p<0.001). In @entity1 with an @entity1465 regression rate over 0.716% in the 2nd week, the hazard ratio for progression to @entity1469 was 3.00 by multivariate analysis (p<0.001). CONCLUSION: Differences in @entity1465 regression rates between spontaneous regression and @entity1469 groups became evident from the second week following molar evacuation. The occurrence of @entity1469 could be predicted as early as the second week by comparing regression rates. @entity1465 regression rate is easily obtainable and a predictive factor for @entity1469 .

title: XXXX chorionic gonadotrophin regression rate as a predictive factor of @entity1469 in high-risk hydatidiform mole: a case-control study.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity1469 :: ('MESH:D031901', 'Disease') :: ['postmolar GTN', 'postmolar gestational trophoblastic neoplasm']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: This study evaluated changes in @entity1421 ( @entity1421 ) levels and related biomarkers in oral @entity75 (OPL) in response to @entity12698 treatment. Twenty-two subjects were enrolled and treated with @entity12698 . Pretreatment and 12-week biopsies were done. Subjects whose biopsy showed >or=30% decrease in @entity1421 remained on @entity12698 for a total of 12 months when repeat biopsy was done. Biopsies were examined to assess degree of @entity1141 , DNA ploidy, and immunohistochemical expression of @entity588 , pAKT-Ser473, Ki-67, and @entity2279 (microvessel density). In 18 paired biopsies available at baseline and 12 weeks, mean normalized @entity1421 levels decreased by 38% (P = 0.002). After 12 months, @entity1421 decreased by 31% (P = 0.340). Twelve biopsies (67%; P = 0.0129) showed improvement in degree of @entity1141 after 12 weeks, and 8 of 11 biopsies (73%; P = 0.0703) continued to show an improvement in the degree of @entity1141 after 12 months. Trends suggested down-modulation of @entity3840 and Ki-67 in some tissues, increased pAKT-Ser473 expression, and an inverse relationship between @entity1421 and @entity588 expression. This study documents the feasibility of measuring potential surrogate endpoint biomarkers of chemopreventive agent response in OPLs. Treatment with @entity12698 in subjects with OPLs favorably modulates the primary mediator of @entity3840 activity, @entity1421 , after 12 weeks.

title: A pilot surrogate endpoint biomarker study of @entity12698 in oral XXXX .

entities_list: @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['premalignant lesions']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE(2)', 'prostaglandin E(2)']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

answer: @entity75 :: (MESH:D001927,Disease) :: ['premalignant lesions']


abstract: Cardiovascular responsiveness to sympathoadrenergic activation obtained by muscle exercise in the supine position was evaluated in 22 @entity1 with @entity82 (11 alcoholic, 11 postnecrotic/cryptogenic; 14 with @entity843 ) and 10 controls of comparable age. Plasma @entity1063 , heart rate, diastolic arterial pressure and cardiac function, as evaluated by systolic time intervals, were monitored. At rest, cirrhotics had higher @entity1063 (154 +/- 19 S.E.M. ng/l) and heart rate (79 +/- 2 beats per min) than controls (71 +/- 3 ng/l, p less than 0.01; 67 +/- 2 beats per min, p less than 0.001), whereas diastolic arterial pressure was similar. Among systolic time intervals, electromechanical systole, pre-ejection period, electromechanical delay and pre-ejection period to left ventricular ejection time ratios were prolonged (p less than 0.05 or less). Exercise led to significant increases in plasma @entity1063 , heart rate and diastolic arterial pressure in both controls and @entity1 . In the latter, however, whereas the increase in @entity1063 was greater (p less than 0.001), those in heart rate and diastolic arterial pressure were less (p less than 0.005). As expected, most systolic time intervals shortened, but the decrease in pre-ejection period (p less than 0.05), isometric contraction time (p less than 0.02) and pre-ejection period to left ventricular ejection time ratio (p = 0.06) was less in @entity1 than in controls. Direct correlations between exercise-induced changes in @entity1063 and both diastolic arterial pressure (r = 0.81; p less than 0.005) and heart rate (r = 0.85; p less than 0.002) were observed in controls, while inverse correlations (r = -0.67, p less than 0.001 and r = -0.44; p less than 0.05) were found in cirrhotics. These results suggest that cardiovascular reactivity to the sympathetic drive is impaired in cirrhotics. The impairment of @entity299 may be due to altered electromechanical coupling.

title: Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in XXXX with @entity82 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac contractility']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: To establish a relation between the survival rate of island skin flaps submitted to prolonged @entity63 and the effect of streptokinase and @entity208 administered after the ischemic period. METHODS: A total of 48 male Winstar @entity35 , each weighing between 300 and 350 grams,were separated into four groups of twelve as follows: control, @entity208 , streptokinase and association of @entity208 and streptokinase, were submitted to an epigastric island flap dissection followed by epigastric vessel bundle clamping. Flaps remained this way for 8 hours in normothermic mixed @entity63 . After the ischemic period, clamps were removed and each @entity35 received the therapeutical scheme proposed for the group by intravenous injections. Flap survival analysis was performed on the seventh post operative day. Variance and descriptive analyses (as a percentage of the @entity39 area) as well as @entity31481 multiple comparisons among the 4 groups and median tests were carried out. RESULTS: @entity35 in the control group presented an average of 79.88% of @entity39 in the flap total area; those which received @entity208 presented an average of 64.05% of @entity39 whereas the group which received streptokinase showed an average of 55.52% of @entity39 . With the association of both drugs, @entity35 presented an average of 54.30% of @entity39 in the flap total area. By applying Dunnet test and the median test, it could be verified that, in this study the streptokinase group had the lowest @entity39 rate. CONCLUSION: The systemic administration of streptokinase after 8 hours of normothermic global @entity63 resulted in an increased survival rate of epigastric island skin flaps in @entity35 , when compared to the administration of @entity208 , association of the two drugs and the control group.

title: [Study of the effect of streptokinase and XXXX in island skin flaps submitted to prolonged @entity63 : experimental study in @entity35 ].

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrotic', 'necrosis']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity208 :: ('MESH:D000493', 'Chemical') :: ['allopurinol']

answer: @entity208 :: (MESH:D000493,Chemical) :: ['allopurinol']


abstract: BACKGROUND AND PURPOSE: We present detailed results of using Neuroform stent-assisted coil @entity887 to treat @entity438 over a three-year period. MATERIAL AND METHODS: Only @entity1 who underwent Neuroform stent-assisted coil @entity887 were included in this study. We assessed @entity1 ' history, @entity439 morphology, indications for stenting, and technical details of the procedures, as well as complications and the midterm follow-up data. RESULTS: This study included 26 @entity1 with 39 @entity439 . A total of 32 of 39 @entity439 were treated by Neuroform stent-assisted @entity887 (SAC), whereas 3 @entity439 were stented without coiling, 2 @entity439 coiled without stenting and 2 @entity439 surgically clipped. The indications for use of stent included @entity439 (n = 28), giant or large @entity439 (n = 6), and @entity439 (n = 5). Of the 32 @entity439 treated with Neuroform SAC, we achieved complete (100%) and near complete (> 95%) occlusion in 27 @entity439 , and partial (< 95%) occlusion in 5 @entity439 . Follow-up angiographic data available in 22 of 32 @entity439 treated with Neuroform SAC (68.7%) demonstrated recanalization in 3 @entity439 (13.6%), and stable occlusion in 19 @entity439 (86.4%). There was no delayed progressive @entity887 or in-stent @entity850 . CONCLUSIONS: Direct and midterm follow-up results confirmed that Neuroform stent-assisted coil @entity887 was a safe and effective technique in the treatment of @entity438 . Although clinically significant complications were uncommon and the evaluation at midterm follow-up is encouraging, further studies need to assess the long-term stability and durability of the stent.

title: Neuroform stent-assisted coil @entity887 : a new treatment strategy for complex XXXX . Results of medium length follow-up.

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['embolization']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'fusiform aneurysms', 'aneurysm', 'broad-neck aneurysms']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['complex cerebral aneurysms']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysms']